Health Care • Biotechnology: Pharmaceutical Preparations
$0.39 ▲ +0.03
(+9.00%)
MKT CAP: $3.0M • VOL: 44.9K
52W L $0 52W H $1
ROARABLE / RQD
D- • 43/100
PIOTROSKI
2 / 9
MBIO // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $0 | $0 | $0 |
| YoY Revenue Growth % | — | — | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$2.4M | -$16.2M | -$49.3M |
| Operating Margin % | — | — | — |
| Net Income (GAAP) | -$1.9M | -$15.8M | -$51.6M |
| EBITDA (Normalized) | — | -$16.2M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$5.3M | -$11.4M | -$49.5M |
| Capital Expenditures (CapEx) | — | $0 | — |
| Free Cash Flow (FCF) | -$5.3M | -$11.4M | -$49.5M |
| FCF Margin % | — | — | — |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $17.3M | $6.8M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $9.5M | -$3.9M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR MBIO.